<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363029">
  <stage>Registered</stage>
  <submitdate>15/03/2013</submitdate>
  <approvaldate>26/03/2013</approvaldate>
  <actrnumber>ACTRN12613000333718</actrnumber>
  <trial_identification>
    <studytitle>Topical Acitretin for the Treatment of rough scaly spots of sun-damaged skin or premalignant condition of thick, scaly, or crusty patches of sun-damaged skin (Facial Actinic Keratosis).</studytitle>
    <scientifictitle>A Double-blind Randomised Placebo-controlled Study of Topical Acitretin and Placebo for the Treatment of Facial Actinic Keratosis.

Protocol Number: DP-001</scientifictitle>
    <utrn>U1111-1134-5593</utrn>
    <trialacronym>ATAK</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Facial actinic keratoses</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Participants are randomised to receive topical acitretin or placebo for 24 weeks. About 1g of Acitretin 0.25% w/w or 0.5% w/w will be applied once daily to the face.  A three week follow-up for all participants occurs at the completion of the treatment phase. The dose concentration is determined by randomisation.</interventions>
    <comparator>Placebo moisturiser gel applied once daily for 24 weeks.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Comparison of the partial clearance rates for each treatment group.  The proportion of participants with 75 % or greater reduction of the number of AK Lesions on the face at the end of treatment compared to baseline. Measured by clinical assessment by the Principal Investigator or Sub-Investigator (lesion count).</outcome>
      <timepoint>24 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Comparison of the total number of all visible or palpable AKs on the entire face at the end of treatment (i.e. those present at baseline and any new lesions) for each treatment group, measured by clinical assessment by the Principal Investigator or Sub-Investigator (lesion count).</outcome>
      <timepoint>24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Comparison of the change in the EIS Score for the entire face by treatment group compared with baseline.</outcome>
      <timepoint>Weeks 8, 16, and 24/end of treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>- At least 3, to a maximum of 25, visible or palpable AK lesions on the face determined by clinical diagnosis.

- Males, or postmenopausal/surgically sterile females.

- Willing and able to comply with the protocol and study requirements.</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>- Atypical AK on the face.

- Diagnosis of SBCC on the face.

- Treatment with oral acitretin.

- Treatment with 5FU, imiquimod, diclofenac, PEP005 or topical retinoids on the face.

- Treatment with a dermatological procedure or surgery on the face.

- Other potentially confounding skin disorders on the face. 

- Females of child bearing potential.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>2/04/2013</anticipatedstartdate>
    <actualstartdate>10/04/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate>11/09/2013</actualenddate>
    <samplesize>75</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Bay of Plenty</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Waikato</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Douglas Pharmaceuticals Ltd</primarysponsorname>
    <primarysponsoraddress>Cnr Te Pai Place and Central Park Drive, 
Lincoln, 
Auckland 0610</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Douglas Pharmaceuticals Ltd</fundingname>
      <fundingaddress>Cnr Te Pai Place and Central Park Drive, 
Lincoln, 
Auckland 0610</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Acitretin is a synthetic retinoid, structurally related to vitamin A. Its efficacy in psoriasis is well known as an oral treatment for severe psoriasis and disorders of keratinisation.  A study of oral acitretin has shown benefit in renal transplant patients with Actinic Keratoses (AKs).  AKs, also referred to as solar keratoses, are premalignant intra-epidermal skin lesions that usually arise in photodamaged skin areas.  Acitretin is therefore expected to be of benefit in the treatment of AK.  Topical acitretin may be associated with few, if any, systemic side effects whilst at the same time producing higher concentrations at the site of treatment compared with oral acitretin.  The efficacy and safety of topical acitretin against a placebo control is to be assessed by a phase 2a study, involving approximately 75 participants in New Zealand.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Northern A Health and Disability Ethics Committee</ethicname>
      <ethicaddress>Ministry of Health
1 the Terrace
PO Box 5013
Wellington
6011</ethicaddress>
      <ethicapprovaldate>16/11/2012</ethicapprovaldate>
      <hrec>12/NTA/56</hrec>
      <ethicsubmitdate>11/10/2012</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Marius Rademaker</name>
      <address>Tristram Clinic
200 Collingwood Street
Hamilton
3204</address>
      <phone>+64 78381035</phone>
      <fax>+64 78382032</fax>
      <email>rademaker@xtra.co.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mrs</title>
      <name>Lindsay Boy</name>
      <address>Douglas Pharmaceuticals Ltd
P.O.Box 45 027,
Te Atatu Peninsula, 
Auckland 0651</address>
      <phone>+ 64 98350660</phone>
      <fax>+ 64 98350690</fax>
      <email>lindsayb@douglas.co.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Miss</title>
      <name>Rhona Macdonald</name>
      <address>Douglas Pharmaceuticals Ltd
P.O.Box 45 027,
Te Atatu Peninsula, 
Auckland 0651</address>
      <phone>+ 64 98350660</phone>
      <fax>+ 64 98350690</fax>
      <email>rhonam@douglas.co.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Marius Rademaker</name>
      <address>Tristram Clinic
200 Collingwood Street
Hamilton
3204</address>
      <phone>+64 78381035</phone>
      <fax>+64 78382032</fax>
      <email>samantham@douglas.co.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>